Vytlačiť
1.
- Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies / Salek T. ... [et al.]. Onkológia. - ISSN 1336-8176. - Roč. 17, č. 2 (2022), s. 139
- C 3069